Healthcare · Drug Manufacturers Specialty Generic · NASDAQ
Alvotech (ALVO) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.53B and a free-cash-flow yield of -12.1%. Over the most recent reported fiscal year, revenue grew 19.7%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 2.8/10
Clearly negative, short of the bottom band. As of Nov 20, 2026.
Momentum
Lagging · +1.4% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-77.1%
How far the last close sits under the highest price of the past five years.
Market cap
$1.53B
Trailing P/E
—
Price / book
—
Price / sales
3.1
FCF yield
-12.1%
Dividend yield
—
Gross margin
60.5%
Operating margin
9.7%
Net margin
-36.5%
Revenue growth (YoY)
+19.7%
Revenue growth (3-yr annual)
+91.8%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.2
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers Specialty Generic
ALVO earnings
Next report: Mar 10, 2027 (Q4 2026, EPS estimate -$0.05).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 10, 2026
-$0.03
-$0.05
+40.0%
$111.40M
Q2 2026
Aug 19, 2026
-$0.11
-$0.08
-37.5%
$105.77M
Q1 2026
May 5, 2026
-$0.09
-$0.07
-28.6%
$105.86M
Q4 2025
Mar 17, 2026
$0.01
-$0.01
+200.0%
$166.57M
ALVO analyst price target
Median target $8.00 from 6 analysts, ranging $4.00 – $9.00.
Nama's AI scorecard currently rates Alvotech Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ALVO report earnings?
Alvotech's next scheduled report is on Mar 10, 2027. Analysts expect EPS of -$0.05.
What is the ALVO price target?
The median analyst price target from 6 analysts is $8.00, with a range of $4.00 – $9.00.
Is ALVO Shariah compliant?
Nama's AAOIFI-style screen reads Alvotech as Not Shariah Compliant. At least one of the three ratios or the industry test failed.